The drug consists of bupivacaine encapsulated in DepoFoam, the company’s technology that allows the analgesic effects to last longer. The drug is designed to provide 72 hours of post-surgical non-opioid pain relief, according to the website. The FDA expects to complete its review of Exparel by July 2011.
Read the Trading Markets report on Exparel.
Read more on anesthesia:
–Anesthesiologist Tasks Colleagues With Peri-Operative Improvement in 2011
–Blocking Receptor Might Help Control Post-Surgery Pain and Inflammation
